Management of Axillary Lymph Nodes in Breast Cancer: a National Patterns of Care Study of 17,151 Patients

Overview

Journal Ann Surg

Specialty General Surgery

Date 1999 Nov 24

PMID 10561093

Citations 4

Authors

D R Brenin

M Morrow

J Moughan

J B Owen

J F Wilson

D P WINCHESTER

Affiliations

Soon will be listed here.

Abstract

Objective: To determine the rates of axillary lymph node dissection (ALND) and axillary irradiation (AI) in patients with breast cancer and to identify the factors influencing them.

Summary Background Data: Routine performance of ALND in the treatment of breast cancer has become controversial. AI has been proposed as an alternative to ALND, and it has been suggested that AI in addition to ALND may decrease local failure in high-risk patients.

Methods: A joint study was conducted by the Commission on Cancer of the American College of Surgeons and the American College of Radiology. A total of 17,151 patients with stage I and II breast cancer treated at 819 institutions in 1994 were studied.

Results: A total of 15,992 patients underwent ALND (93%). The mean ages of patients who did and did not undergo ALND were 60.4 and 73.0 years. Univariate analysis demonstrated significantly decreased rates of ALND for women age 70 or older (86% vs. 97%), patients with clinical T1 a tumors (81% vs. 93%), grade I histology (90% vs. 95%), and patients with favorable tumor types (88% vs. 94%). The ALND rate did not vary between palpable and nonpalpable tumors. Multivariate analysis of variables affecting the rate of ALND identified type of surgery, age, tumor size, histology, and payer status as significant. A total of 889 patients received AI. Patients not undergoing ALND were more likely to receive AI (10% vs. 5%). A total of 1.6% of patients with no lymph node metastasis underwent AI, 8.9% of those with one to three positive nodes underwent AI, 24.0% of those with four to nine positive lymph nodes underwent AI, and 29.9% of those with > or = 10 positive lymph nodes underwent AI. Multivariate analysis of variables affecting the proportion of patients who received AI and had undergone ALND identified nodal status and type of surgery as significant.

Conclusions: Axillary lymph node dissection continues to be routinely applied in the treatment of breast cancer, and AI remains underused in patients at high risk for local regional relapse.

Citing Articles

Sensitivity of imaging for multifocal-multicentric breast carcinoma.

Bozzini A, Renne G, Meneghetti L, Bandi G, Santos G, Vento A BMC Cancer. 2008; 8:275.

PMID: 18826585 PMC: 2576336. DOI: 10.1186/1471-2407-8-275.

Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy.

Langer I, Marti W, Guller U, Moch H, Harder F, Oertli D Ann Surg. 2004; 241(1):152-8.

PMID: 15622003 PMC: 1356858. DOI: 10.1097/01.sla.0000149305.23322.3c.

Axillary lymph node dissection versus the sentinel lymph node technique in breast cancer.

Seigler H Ann Surg. 2004; 240(1):7-8.

PMID: 15213611 PMC: 1356367. DOI: 10.1097/01.sla.0000132567.28613.a7.

Stage and treatment variation with age in postmenopausal women with breast cancer: compliance with guidelines.

Wyld L, Garg D, Kumar I, Brown H, Reed M Br J Cancer. 2004; 90(8):1486-91.

PMID: 15083173 PMC: 2409727. DOI: 10.1038/sj.bjc.6601742.

References

Fisher E, Sass R, Fisher B . Pathologic findings from the National Surgical Adjuvant Project for Breast Cancers (protocol no. 4). X. Discriminants for tenth year treatment failure. Cancer. 1984; 53(3 Suppl):712-23. DOI: 10.1002/1097-0142(19840201)53:3+<712::aid-cncr2820531320>3.0.co;2-i. View

PETERS G, Wolff M, HAAGENSEN C . Tubular carcinoma of the breast. Clinical pathologic correlations based on 100 cases. Ann Surg. 1981; 193(2):138-49. PMC: 1345032. DOI: 10.1097/00000658-198102000-00003. View

Fowble B . Postmastectomy radiation: a modest benefit prevails for high risk patients. Cancer. 1997; 79(6):1061-6; discussion 1067-8. DOI: 10.1002/(sici)1097-0142(19970315)79:6<1061::aid-cncr1>3.0.co;2-j. View

Diab S, Hilsenbeck S, de Moor C, Clark G, Osborne C, Ravdin P . Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol. 1998; 16(5):1655-60. DOI: 10.1200/JCO.1998.16.5.1655. View

Barth A, CRAIG P, Silverstein M . Predictors of axillary lymph node metastases in patients with T1 breast carcinoma. Cancer. 1997; 79(10):1918-22. View

Pierce S, Recht A, Lingos T, Abner A, Vicini F, Silver B . Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. Int J Radiat Oncol Biol Phys. 1992; 23(5):915-23. DOI: 10.1016/0360-3016(92)90895-o. View

Cerrotta A, Lozza L, Kenda R, Gardani G, Galante E, ZUCALI R . Current controversies in the therapeutic approach to early breast cancer in the elderly. Rays. 1997; 22(1 Suppl):66-8. View

Recht A, Pierce S, Abner A, Vicini F, OSTEEN R, Love S . Regional nodal failure after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol. 1991; 9(6):988-96. DOI: 10.1200/JCO.1991.9.6.988. View

Petrek J, Blackwood M . Axillary dissection: current practice and technique. Curr Probl Surg. 1995; 32(4):257-323. DOI: 10.1016/s0011-3840(05)80015-2. View

10.

Graversen H, Blichert-Toft M, Andersen J, Zedeler K . Breast cancer: risk of axillary recurrence in node-negative patients following partial dissection of the axilla. Eur J Surg Oncol. 1988; 14(5):407-12. View

11.

Pierquin B, Mazeron J, Glaubiger D . Conservative treatment of breast cancer in Europe: report of the Groupe Européen de Curiethérapie. Radiother Oncol. 1986; 6(3):187-98. DOI: 10.1016/s0167-8140(86)80153-0. View

12.

Fowble B, Gray R, Gilchrist K, Goodman R, Taylor S, Tormey D . Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. J Clin Oncol. 1988; 6(7):1107-17. DOI: 10.1200/JCO.1988.6.7.1107. View

13.

Ragaz J, Jackson S, Le N, Plenderleith I, Spinelli J, Basco V . Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997; 337(14):956-62. DOI: 10.1056/NEJM199710023371402. View

14.

Wong J, Recht A, Beard C, Busse P, Cady B, Chaffey J . Treatment outcome after tangential radiation therapy without axillary dissection in patients with early-stage breast cancer and clinically negative axillary nodes. Int J Radiat Oncol Biol Phys. 1997; 39(4):915-20. DOI: 10.1016/s0360-3016(97)00456-2. View

15.

Fisher B, Redmond C, Fisher E, Bauer M, Wolmark N, Wickerham D . Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med. 1985; 312(11):674-81. DOI: 10.1056/NEJM198503143121102. View

16.

Leung S, Otmezguine Y, Calitchi E, Mazeron J, Le Bourgeois J, Pierquin B . Locoregional recurrences following radical external beam irradiation and interstitial implantation for operable breast cancer--a twenty three year experience. Radiother Oncol. 1986; 5(1):1-10. DOI: 10.1016/s0167-8140(86)80002-0. View

17.

Cady B . Case against axillary lymphadenectomy for most patients with infiltrating breast cancer. J Surg Oncol. 1997; 66(1):7-10. DOI: 10.1002/(sici)1096-9098(199709)66:1<7::aid-jso3>3.0.co;2-8. View

18.

. Consensus statement: treatment of early-stage breast cancer. National Institutes of Health Consensus Development Panel. J Natl Cancer Inst Monogr. 1992; (11):1-5. View

19.

MCDIVITT R, Boyce W, Gersell D . Tubular carcinoma of the breast. Clinical and pathological observations concerning 135 cases. Am J Surg Pathol. 1982; 6(5):401-11. DOI: 10.1097/00000478-198207000-00002. View

20.

Overgaard M, Hansen P, Overgaard J, Rose C, Andersson M, Bach F . Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1998; 337(14):949-55. DOI: 10.1056/NEJM199710023371401. View